Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.

39 It is also consistent with, for example, a previously published analysis pooling data from three randomized clinical trials, where CDK4/6i therapy in combination with an AI resulted in numerically higher median PFS in patients ≥75 years with HR+, HER2− aBC compared with those <75 years (mPFS 31.1 months versus 27.6 months), although the observed differences did not reach statistical significance. 40 Irrespective of the apparent initial age-group cPFS difference observed in this RIBANNA analysis, it is encouraging to see that for both age groups 2-year cPFS increased over time.

also in 111,027 other papers

The probability of being event free (surviving or having no progress) for an additional 2 years showed a trend of increasing from 61.75% to 62.95%, 65.65%, and 72.74% in patients being free from progression for 12, 24, and 36 months, respectively ( Figure 3 ).

also in 53,322 other papers